Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability -

Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability
Information type: Other primary research
Source: British Journal of Clinical Pharmacology
Specialities: Respiratory disorders
Summary
In this retrospective analysis in Germany of patients on tiotropium only 30% of patients on treatment could theoretically be included in the TIOSPIR trial due to the exclusion criteria. The authors highlight the TIOSPIR trial may have excluded significant “real-life” usage.
UKMi comment
Results from the TIOSPIR trial had suggested that the Tiotropium Respimat® device is non-inferior to the HandiHaler® device in terms of risk of death and risk of first post treatment exaccerbation.
Related links: TIOSPIR study